e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 20, 2007
Pharmion Corporation
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-50447   84-1521333
         
(State or other jurisdiction
of incorporation) 		  (Commission File
Number) 		  (IRS Employer
Identification No.)
     
2525 28th Street, Boulder, Colorado   80301
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code 720-564-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01   Other Events.
     On August 20, 2007, Pharmion Corporation announced that it had entered into a research collaboration with MethylGene, Inc. for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01   Financial Statements and Exhibits.
(d) Exhibits
     
Exhibit    
Number   Description
 
    
99.1
  Press Release, dated August 20, 2007, issued by Pharmion Corporation announcing a research collaboration with MethylGene, Inc.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  PHARMION CORPORATION
 		  
Date: August 21, 2007  By:   /s/ Erle T. Mast    
    Name:   Erle T. Mast    
    Title:   Chief Financial Officer   
 

 

 

EXHIBIT INDEX
     
Exhibit    
Number   Description
 
    
99.1
  Press Release, dated August 20, 2007, issued by Pharmion Corporation announcing a research collaboration with MethylGene, Inc.